Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management (IMAGE)
Caption
- AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class, brain-penetrant, non-opioid solution for pain management.
- Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated superior efficacy compared to the standard of care, along with a favorable safety profile as an oral treatment, and promising DMPK properties.
- Proven Reproducibility and Scale: As Insilico’s 31st PCC nominated since 2021, ISM9528 further validates the capabilities of Insilico's proprietary Pharma.AI platform to consistently accelerate and empower drug R&D innovation.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content